<DOC>
	<DOCNO>NCT00960856</DOCNO>
	<brief_summary>The primary objective study characterize single-dose pharmacokinetic profile fenofibric acid ( 105 mg tablet ) effect food various calorie/fat composition rate extent absorption . Additionally , safety tolerability dose regimen fenofibric acid evaluate .</brief_summary>
	<brief_title>Four Arm Food Effect Study Fenofibric Acid Tablets</brief_title>
	<detailed_description>The primary objective study determine single-dose pharmacokinetic profile fenofibric acid ( 105 mg tablet ) effect food various calorie/fat composition rate extent absorption . Forty healthy , non-smoking , non-obese , non-pregnant adult volunteer age 18 45 year old receive single oral dose fenofibric acid one four randomly assign sequence meal condition separate 7 day washout period . On study Days 1 , 8 , 15 22 subject receive single oral dose ( 1 x 105 mg tablet ) fenofibric acid follow overnight fast least 10 hour low-fat meal , standard meal , high-fat/high-calorie meal accord randomization sequence . Subjects fast least 4.25 hour dose four dose condition . Blood sample draw participant dose 72 hour post-dose time sufficient adequately define pharmacokinetics fenofibric acid . A goal study evaluate safety tolerability regimen healthy volunteer . Seated blood pressure heart rate measure prior dose 2 hour post-dose . Subjects monitor throughout confinement portion study adverse reaction study drug and/or procedure . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate Investigator report subject 's case report form .</detailed_description>
	<mesh_term>Fenofibric acid</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Healthy adult age 18 45 Nonsmoking Nonpregnant ( postmenopausal , surgically sterile , use effective contraceptive measure ) Body mass index ( BMI ) less 30 Medically healthy basis medical history physical examination Hemoglobin &gt; = 12g/dL Completion screen process within 28 day prior dose Provision voluntary write informed consent Recent participation ( within 28 day ) research study Recent significant blood donation plasma donation Pregnant lactate Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Recent ( 2year ) history evidence alcoholism drug abuse History presence significant cardiovascular , pulmonary , hepatic , gallbladder biliary tract , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 28 day prior first dose throughout study Drug allergy fenofibric acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>pharmacokinetics</keyword>
</DOC>